|
Left atrial appendage closure (LAAC) is a treatment strategy to reduce the risk of left atrial appendage blood clots from entering the bloodstream and causing a stroke in patients with non-valvular atrial fibrillation (AF). In non-valvular AF, over 90% of stroke-causing clots that come from the heart are formed in the left atrial appendage. The most common treatment for AF stroke risk is treatment with blood-thinning medications, also called oral anticoagulants, which reduce the chance for blood clots to form. These medications (which include warfarin, commonly referred to as Coumadin®, and other newer approved blood thinners) are very effective in lowering the risk of stroke in AF patients. Most patients can safely take these medications for years (and even decades) without serious side effects. However, some patients find that blood thinning medications can be difficult to tolerate or are risky. Because they prevent blood clots by thinning the blood, blood thinners can increase the risk of bleeding problems. In select patients, physicians determine that an alternative to blood thinners is needed to reduce AF stroke risk. Approximately 45% of patients who are eligible for warfarin are not being treated, due to tolerance or adherence issues.〔Jani, et al(April 2014). "Uptake of Novel Oral Anticoagulants in Patients with Non-Valvular and Valvular Atrial Fibrillation: Results from the NCDR-Pinnacle Registry" ''J Am Coll Cardiol'' 63 (12). Table 1.〕 This applies particularly to the elderly, although studies have indicated that they can also benefit from anticoagulants. Left atrial appendage closure is an implant-based alternative to blood thinners. Like blood thinning medications, an LAAC implant does not cure AF. A stroke can be due to factors not related to a clot traveling to the brain from the left atrial. Other causes of stroke can include high blood pressure and narrowing of the blood vessels to the brain. An LAAC implant will not prevent these other causes of stroke. ==Devices and alternatives== On March 13, 2015, the U.S. Food and Drug Administration approved the WATCHMAN™ LAAC Implant, from Boston Scientific, to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular AF who are at increased risk of stroke and are recommended for blood thinning medicines, are suitable for warfarin and have an appropriate reason to seek a non-drug alternative to warfarin. The WATCHMAN Implant was studied in two randomized clinical trials and several clinical registries.〔(WATCHMAN LAA Closure Technology – P130013 ). (US Food and Drug Administration), April 2015.〕 The implant was approved in Europe in 2005. The WATCHMAN Implant is a one-time implant typically performed under general anesthesia. Similar to a stent procedure, the device is guided into the heart through a flexible tube (catheter) inserted through the femoral vein in the upper leg. The implant is introduced into the right atrium and is then passed into the left atrium through a patent foramen ovale or through a puncture hole.〔(WATCHMAN Left Atrial Appendage Closure Device with Delivery System ). 14 (Boston Scientific), March 2015.〕 These small iatrogenic atrial septal defects usually disappear within six months.〔 Once the position is confirmed, the implant is released and is left permanently fixed in the heart. The implant does not require open heart surgery and does not need to be replaced. Recovery typically takes twenty-four hours.〔 Following implantation, a transesophageal echocardiography has to be performed to judge completeness of closure and the presence of blood clots. Warfarin is needed for at least 45 days following implantation of the WATCHMAN Implant to allow blood vessel lining to form around the device (endothelialization). Once a patient stops taking warfarin, clopidogrel and aspirin are taken for 6 months after implant. Patients need to use aspirin indefinitely.〔 In the PREVAIL clinical trial, 92% of patients stopped taking warfarin after 45 days and 99% discontinued warfarin at 1 year. Another device termed PLAATO (percutaneous left atrial appendage transcatheter occlusion) was the first LAA occlusion device, although it is no longer being developed by its manufacturer (Appriva Medical, Inc. from Sunnyvale, CA). In 210 patients receiving the PLAATO device, there was an estimated 61% reduction in the calculated stroke risk. The Amplatzer device from St. Jude Medical, used to close atrial septal defects, has also been used to occlude the left atrial appendage.〔name=pmid14571497>〕 This can be performed without general anaesthesia and without echocardiographic guidance. Transcatheter patch obliteration of the LAA has also been reported.〔 Other devices exist to occlude the left atrial appendage from the inside of the heart such as the Wavecrest device and the Lariat device. The latter technique entails closing a strangling noose around the LAA, which is advanced from the chest wall with a special sheath, after introducing a balloon in the LAA from the inside surface of the heart (endocardium). The LAA can also be surgically removed simultaneous with other cardiac procedures such as the maze procedure or during mitral valve surgery. Finally, the left atrial appendage has been closed in a limited number of patients using a chest keyhole surgery approach. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Left atrial appendage occlusion」の詳細全文を読む スポンサード リンク
|